● Covered by 1 source · 2 reportsLow impact2 positive
RonanRX (YC S26) Launches Personalized GLP-1 Care Service
Key points
- RonanRX offers personalized GLP-1 treatments.
- Physicians set individual dose curves and titration schedules.
- Patient-specific adjuncts like B12 or anti-nausea support are provided.
- Licensed pharmacists verify and release prescriptions.
- RonanRX is a Y Combinator S26 startup.
- RonanRX combines software for prescribing, telehealth, compounding, manufacturing, and delivery.
- Founder Lloyd previously built a mask manufacturing factory during the pandemic.
- The mask factory produced one million masks daily and generated $50 million in revenue.
- Lloyd used tirzepatide, a GLP-1 medication, for weight loss.
Personalized GLP-1 Treatment Approach
RonanRX, a Y Combinator S26 company, has introduced a new service focused on personalized GLP-1 care. The company states that standard GLP-1 plans often use a one-size-fits-all approach for dosing and titration, which can lead to side effects and patient discontinuation. RonanRX aims to customize treatment based on individual patient history, body response, and tolerance.
Physician-Led Dosing and Adjuncts
The service involves a physician reviewing the patient's medical history and lab results to establish a personalized starting dose and titration schedule. This approach allows for adjustments as treatment progresses, moving away from fixed-label prescriptions. Additionally, physicians can prescribe patient-specific adjuncts, such as B12 or anti-nausea support, to improve tolerability and consistency of the GLP-1 treatment.
Prescription Verification and Future Plans
RonanRX emphasizes a clear authority chain where the physician determines the patient-specific prescription. A licensed pharmacist at the patient's chosen pharmacy then verifies and releases only the ordered medication. The company also indicated plans to expand into other areas, with hormone therapy and more services listed as 'on the way', including a waitlist for HRT.
Addressing Common GLP-1 Challenges
The company highlights that common side effects like nausea and fatigue, often unaddressed in standard plans, can be managed with personalized support. RonanRX also notes that high cash-pay prices for brand-name GLP-1s can lead patients to ration doses or discontinue treatment. The personalized approach aims to provide a more tailored and supported experience for patients.
Updates
- RonanRX is a Y Combinator S26 startup.
- RonanRX combines software for prescribing, telehealth, compounding, manufacturing, and delivery.
- Founder Lloyd previously built a mask manufacturing factory during the pandemic.
- The mask factory produced one million masks daily and generated $50 million in revenue.
- Lloyd used tirzepatide, a GLP-1 medication, for weight loss.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
The daily brief
One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.
One email a day. Unsubscribe in one click, any time.
Today's brief
Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.
▶ Play today's brief
New every morning, and the back catalogue is archived by date.
Primary sources
GitHub HackerNews/APIHow outlets covered it
RonanRx, a Y Combinator S26 startup, has launched with a focus on creating a vertically integrated pharmaceutical company for personalized peptides and GLP-1 medications. The company aims to combine software for prescribing, telehealth, compounding, manufacturing, and delivery to address the disconnected nature of current pharmaceutical processes.
RonanRX, a Y Combinator S26 startup, launched a service offering personalized GLP-1 treatments, including physician-reviewed dosing and patient-specific adjuncts. The service aims to address issues with standard GLP-1 plans, such as fixed dosing and lack of side effect management, by tailoring treatment to individual patient histories and responses.